Scalper1 News
Massive EPS gains one year might mean that a company tops out the next. While the five IBD 50 stocks in today’s screen are set to show 2014 EPS growth that leaves 2013 in the dust, the years beyond might not be as bountiful. Shares of Gilead Sciences (GILD) have launched upward since its hepatitis C drug Sovaldi debuted last year. The company’s full-year 2014 EPS is expected to grow 290% year over year to $7.95, partly on Sovaldi and Harvoni — Scalper1 News
Scalper1 News